Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/43847
Campo DC Valoridioma
dc.contributor.authorBordón Rodríguez, Elisa de los Reyesen_US
dc.contributor.authorLeón, Leticia G.en_US
dc.contributor.authorRíos-Luci, Carlaen_US
dc.contributor.authorLara, Pedro C.en_US
dc.contributor.authorPadrón, José M.en_US
dc.date.accessioned2018-11-21T18:17:45Z-
dc.date.available2018-11-21T18:17:45Z-
dc.date.issued2012en_US
dc.identifier.issn1871-5206en_US
dc.identifier.urihttp://hdl.handle.net/10553/43847-
dc.description.abstractDTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.en_US
dc.languageengen_US
dc.publisher1871-5206-
dc.relation.ispartofAnti-Cancer Agents in Medicinal Chemistryen_US
dc.sourceAnti-Cancer Agents in Medicinal Chemistry [ISSN 1871-5206], v. 12, p. 988-993en_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherAnticancer drugsen_US
dc.subject.otherAntiproliferativeen_US
dc.subject.otherCanceren_US
dc.subject.otherCatalytic inhibitoren_US
dc.subject.otherCell linesen_US
dc.subject.otherChemoradiotherapyen_US
dc.subject.otherChemotherapyen_US
dc.subject.otherDNAen_US
dc.subject.otherDrug combinationsen_US
dc.subject.otherMechanism of actionen_US
dc.subject.otherMedian drug effecten_US
dc.subject.otherMitosisen_US
dc.subject.otherRadiation therapyen_US
dc.subject.otherScreeningen_US
dc.subject.otherTopoisomeraseen_US
dc.titleIn vitro synergistic interaction between DTA0100 and radiation in human cancercell linesen_US
dc.typeinfo:eu-repo/semantics/articlees
dc.typeArticlees
dc.identifier.doi10.2174/187152012802650057en_US
dc.identifier.scopus2-s2.0-84866413012-
dc.contributor.authorscopusid24402677200-
dc.contributor.authorscopusid12785710200-
dc.contributor.authorscopusid26867999100-
dc.contributor.authorscopusid7004374085-
dc.contributor.authorscopusid7003856521-
dc.description.lastpage993-
dc.description.firstpage988-
dc.relation.volume12-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.identifier.ulpgces
dc.description.sjr1,007
dc.description.jcr2,61
dc.description.sjrqQ2
dc.description.jcrqQ2
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.fullNameBordón Rodríguez, Elisa de los Reyes-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

2
actualizado el 14-abr-2024

Visitas

48
actualizado el 22-jul-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.